Skip to main content
Premium Trial:

Request an Annual Quote

T2 Biosystems Gets FDA 510(k) Clearance for Biothreat Panel

NEW YORK – T2 Biosystems announced on Tuesday that it has obtained 510(k) clearance from the US Food and Drug Administration for its T2Biothreat Panel.

The panel is now the only FDA-cleared multi-target biothreat product developed and manufactured by a US-owned company, the Lexington, Massachusetts-based firm said in a statement.

"With receipt of the FDA 510(k) clearance, which we believe demonstrates unparalleled sensitivity and specificity in direct-from-blood multi-target biothreat detection, we have immediately shifted our focus to commercialization of the T2Biothreat Panel, which we intend to sell to commercial markets and governments," T2 Biosystems Chairman and CEO John Sperzel said in a statement.

The biothreat panel detects six organisms directly from blood using the T2Dx instrument. Specifically, it detects the organisms that cause anthrax (Bacillus anthracis), tularemia (Francisella tularensis), glanders (Burkholderia mallei), melioidosis (Burkholderia pseudomallei)plague (Yersinia pestis), and typhus (Rickettsia prowazekii).

The US clinical evaluation to support the FDA 510(k) submission included testing of the T2Biothreat Panel at MRIGlobal, a Biosafety Level 3 laboratory specializing in biothreat pathogens, and at Ochsner Medical Center.

In its statement, T2 said that the clinical evaluation assessed the sensitivity and specificity of the panel to detect targets in blood samples containing a range of bacterial concentrations. The positive percent agreement for all targets at 1 to 3 times the limit of detection was 100 percent for all targets except F. tularensis, which was 94.3 percent. The negative percent agreement for all six targets in blood from healthy or febrile patients containing no bacteria was 100 percent.

The T2Biothreat Panel has been funded in part by a $62 million contract from the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.